ClinConnect ClinConnect Logo
Search / Trial NCT00206635

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Launched by BAYER · Sep 13, 2005

Trial Information

Current as of June 06, 2025

Completed

Keywords

ClinConnect Summary

This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients in North America have to have been previously enrolled in the original Betaseron trial from 1988-1993
  • Be able to understand the consent form (or have a guardian who can)
  • Exclusion Criteria:
  • North American patients cannot be included if they have not participated in the original Betaseron trial from 1988-1993

About Bayer

Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.

Locations

Many Locations, Alabama, United States

Many Locations, British Columbia, Canada

Patients applied

0 patients applied

Trial Officials

Bayer Study Director

Study Director

Bayer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials